Literature DB >> 11678459

Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product.

M Kajitani1, A Ozdemir, M Aguinaga, A R Jazieh, J T Flick, T Antakli.   

Abstract

Hemorrhagic complications have been reported after repeated exposures to bovine thrombin products due to development of factor V inhibitors. Our patient underwent emergency repair of acute aortic dissection and coronary artery bypass grafting. The patient developed leg wound infection at the saphenous vein harvest site, which was debrided and left open. Attempt to reclose the leg wound 1 month later was complicated by a life-threatening hemorrhage with markedly elevated activated partial thromboplastin time. There was no evidence of infection or disseminated intravascular coagulation, and further study identified low factor V level with positive factor V inhibitor. Treatment with plasmapheresis and steroid successfully reversed the coagulopathy. Detailed case review failed to reveal exposure to any thrombin products other than the one used for the aortic dissection repair. This case was unusual because only a single exposure to this product resulted in severe hemorrhagic complication 1 month after surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11678459     DOI: 10.1111/j.1540-8191.2000.tb01296.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  8 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Whole blood thrombin: development of a process for intra-operative production of human thrombin.

Authors:  Vijay Kumar; John R Chapman
Journal:  J Extra Corpor Technol       Date:  2007-03

3.  Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: report of two cases.

Authors:  Tomoya Miura; Daisuke Ban; Takatoshi Koyama; Atsushi Kudo; Takanori Ochiai; Takumi Irie; Noriaki Nakamura; Shinji Tanaka; Shigeki Arii
Journal:  Surg Today       Date:  2013-05-23       Impact factor: 2.549

4.  Stability of human thrombin produced from 11 ml of plasma using the thrombin processing device.

Authors:  Vijay Kumar; Trista Madsen; Haihong Zhu; Elisabeth Semple
Journal:  J Extra Corpor Technol       Date:  2005-12

5.  Thrombin use in surgery: an evidence-based review of its clinical use.

Authors:  Sung W Ham; Wesley K Lew; Fred A Weaver
Journal:  J Blood Med       Date:  2010-07-22

6.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

7.  Clinical use of topical thrombin as a surgical hemostat.

Authors:  Wesley K Lew; Fred A Weaver
Journal:  Biologics       Date:  2008-12

8.  Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia.

Authors:  Fuka Mima; Ryota Minami; Mizuki Asako; Hitomi Matsunaga; Yuri Fujita; Yoshimi Takimoto; Sonoko Senda; Wataru Nakahara; Mako Ikeda; Shuji Ueda
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.